Randomized trial to assess the efficacy and safety of xyloglucan for the treatment of acute gastroenteritis in children release_lb3wthymrzgshhnv5jzrc7fuju

by Maria Jose Perez‐Garcia, ana, Francisco‐Javier Rodriguez‐Contreras, Maria Angeles PandoBravo, Cristina Chiatti, Carmen Ramos, Mario Arana‐Zumaquero, Maria Isabel Gonzalez‐Marcos, Juncal Diaz, Maria Cristina Fresno‐Calle, Ruth García‐Bartolomé, Susana Viver (+6 others)

Published in Food Science & Nutrition by Wiley.

2023   Volume 11, Issue 12, p7698-7706

Abstract

<jats:title>Abstract</jats:title>Acute gastroenteritis is one of the most common diseases in children and an important cause of morbidity and mortality worldwide. No specific treatment is available; therefore, management is exclusively symptomatic. Xyloglucan has been approved in Europe as a class IIa medical device for restoration of the physiological functions of the intestinal wall. Our objective was to assess efficacy and safety of xyloglucan for the treatment of acute gastroenteritis in children. We performed a triple‐blind, randomized placebo‐controlled clinical trial in four primary care centers and one continued care hospital center. The study population comprised children with acute gastroenteritis aged &gt;3 months and &lt;5 years. Our primary endpoint was time (in hours) of resolution of diarrhea, defined as the time to resolution of stool consistency (Bristol Stool Form Scale ≤5 or Amsterdam Stool Form Scale B or C) or time until deposition frequency resumes to normality, whichever occurred first. We also recorded intravenous rehydration, hospitalization, stools per day, Vesikari scale, vomiting, relapse, weight loss, drugs prescribed, and adverse events. Eighty children were included in the intention‐to‐treat population (43 xyloglucan and 37 placebo) and 74 (93%) in the per‐protocol population. Time to resolution of diarrhea was similar in both groups with (median, 95% CI) 24, 17–24 h in the xyloglucan group versus 24, 19–24 h in the placebo group, <jats:italic>p</jats:italic> = .680. Significant differences were observed for patients with moderate‐to‐severe diarrhea (Vesikari scale ≥9): xyloglucan group (20 [15–24] h) versus placebo group (85 [51–120] h) (<jats:italic>p</jats:italic> = .04). No other significant differences were found. Xyloglucan can be considered safe and other studies should be performed to confirm the usefulness in patients with moderate‐to‐severe diarrhea.
In application/xml+jats format

Archived Files and Locations

application/pdf   650.5 kB
file_ezhrabahyngvdevd5p4ed2m4fu
europepmc.org (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2023-09-25
Language   en ?
DOI  10.1002/fsn3.3688
PubMed  38107106
PMC  PMC10724600
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  2048-7177
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 2b114f8f-8e9c-4d76-8eef-67f52151a458
API URL: JSON